Anders Ullén, Christof Vulsteke, Jens Bedke, Steffen Rausch, Shilpa Gupta, Seok-Ho Kang, Jeanny B. Aragon-Ching, Laura Bernal Vaca, Viktor Paramonov, Avivit Peer, Viktor Stus, Vagif Atduev, Keita Nakane, Jasmine Lichfield, Changting Meng, David Huang, Chethan Ramamurthy, Blanca Homet Moreno, Matthew D. Galsky. "Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.638